This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
Using adjuvant lamotrigine plus older AEDs the additional seizure free days gained were 10.8 in year 1, 31.2 in year 2 and 25.18 days in years 3-10.
Measure of benefits used in the economic analysis
The benefit measure was seizure-free days gained. Benefits were discounted at a rate of 3%.
Direct costs
Costs were determined from the perspective of the health care system. Data on the costs of treatment and resource use for intractable seizures were derived from literature published before the availability of the new AEDs. Resource use for patients receiving lamotrigine were taken from published clinical trials. The average wholesale price for lamotrigine, reported in the 1995 Drug Topic Red Book, was used in estimating costs of drug use. Where data were not available, experts were consulted for clinical relevance of cost and resource data. Costs and benefits were discounted at a rate of 3% per annum. The base price year used was not stated.
Indirect Costs
Not included.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were conducted varying a number of parameters such as the probability of surgery in the second year, costs of treatment, and hospitalisation rates. The precise types of sensitivity analyses used were not reported.
Estimated benefits used in the economic analysis
In the base case scenario, over the 10 year period, 106 seizure free days per patient would be gained.
Cost results
The 10 year total costs for the lamotrigine group and the AED group alone were not reported, although the incremental cost of lamotrigine would be $728. Total costs per patient for the two groups respectively in year one would be $3,130 and $2,224 and in year two these costs would be $10,560 and $14,146. The costs of required treatment for patients in years 3 -10 were $2,172 (lamotrigine) and $1,762 (AED). Adverse events including the need for surgery were included in these cost estimates.
Synthesis of costs and benefits
The incremental cost per seizure free day gained was $6.90. The baseline results were sensitive to the results of sensitivity analysis, in particular the estimates of the impact of the intervention on the need for surgery and surgical evaluation and the numbers of seizure free days gained each year. Incremental cost effectiveness per seizure free day gained varied between $-5.61 and $63.60
Authors' conclusions
The additional costs of adjuvant lamotrigine therapy for patients with refractory epilepsy are likely to be offset by reduction in the need for other medical procedures, in particular surgery and surgical evaluation.
CRD COMMENTARY -Selection of comparators
A justification was provided for the comparators used, as these were older AEDs used for the treatment of refractory epilepsy without adjuvant therapy using a newer AED. Other interventions are available for the treatment of epilepsy, but the authors stated that there was a lack of available clinical data.
Validity of estimate of measure of benefit
Estimates of clinical benefit were taken from published controlled clinical trials. However, this estimate may be subject to bias, as the paper does not report on the methods used to identify and pool results from the literature. Furthermore, the paper does not appear to indicate clearly how many clinical trials were used in the analysis.
Validity of estimate of costs
Sufficient detail is provided on the source and estimate of costs, although the price years used were not clearly stated. However, as noted by the authors, much of this information could not be found from observational data, and instead, assumptions had to be made by the authors. Sensitivity analysis demonstrated that differences in assumptions on costs and resource use could lead to much variance in cost-effectiveness ratios. The authors noted that indirect costs were not included due to a lack of information. Future analysis should consider these other costs, as the authors themselves estimated that these may represent more than 60% of the total costs of care for epilepsy patients.
Other issues
The cost-effectiveness estimates reported by the authors are unlikely to be generalisable to other settings and should be viewed as an indication that more work is required to compare the effectiveness of treatments for epilepsy, and in particular to consider the consequences of treatments in relation to the demand for additional medical resources such as surgical procedures.
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